Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions

20 marzo 2014 aggiornato da: Boston Scientific Corporation

NG PROMUS: A Prospective, Multicenter Trial to Assess the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) for the Treatment of Atherosclerotic Lesion(s)

NG PROMUS: A Prospective, Multicenter Trial to Assess the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) for the Treatment of Atherosclerotic Lesion(s)

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

To evaluate clinical and peri-procedural angiographic and intravascular ultrasound (IVUS) outcomes for the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) in the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by visual estimate) in native coronary arteries ≥ 2.50 mm to ≤ 4.0 mm in diameter (by visual estimate)

Tipo di studio

Interventistico

Iscrizione (Effettivo)

100

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Australia
    • Western Australia
      • Fremantle, Western Australia, Australia, 6160
        • Fremantle Hospital
  • Nuova Zelanda
      • Auckland, Nuova Zelanda, 1010
        • Auckland City Hospital
      • Auckland, Nuova Zelanda, 1003
        • Mercy Angiography Unit, Ltd. Mercy Hospital
      • Auckland, Nuova Zelanda, 1030
        • North Shore Hospital
      • Auckland, Nuova Zelanda, 1546
        • Ascot Angiography
      • Christchurch, Nuova Zelanda, 8140
        • Christchurch
      • Otahuhu, Nuova Zelanda, 1640
        • Middlemore Hospital
  • Singapore
      • Singapore, Singapore, 119228
        • National University Hospital Singapore
      • Singapore, Singapore, 168752
        • National Heart Center Singapore

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Clinical Inclusion Criteria:

  1. Subject must be at least 18 years of age
  2. Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed
  3. Subject is eligible for percutaneous coronary intervention (PCI)
  4. Subject has symptomatic coronary artery disease with objective evidence of ischemia or silent ischemia
  5. Subject is an acceptable candidate for coronary artery bypass grafting (CABG)
  6. Subject is willing to comply with all protocol-required follow-up evaluation

Angiographic Inclusion Criteria:

  1. Target lesion(s) must be located in a native coronary artery with a visually estimated reference vessel diameter (RVD) ≥2.50 mm and ≤4.0 mm
  2. Target lesion(s) length must be ≤34 mm (by visual estimate)
  3. Target lesion(s) must have visually estimated stenosis ≥50% and <100% with thrombolysis in Myocardial Infarction (TIMI) flow >1 and one of the following (stenosis ≥70%, abnormal fractional flow reserve (FFR), abnormal stress test or imaging stress test, or elevated biomarkers) prior to procedure
  4. Coronary anatomy is likely to allow delivery of a study device to the target lesions(s)
  5. The first lesion treated must be successfully pre-dilated/pretreated Note: Successful pre-dilatation/pretreatment refers to dilatation with a balloon catheter of appropriate length and diameter, or pretreatment with directional or rotational coronary atherectomy, laser or cutting/scoring balloon with no greater than 50% residual stenosis and no dissection greater than National Heart, Lung, Blood Institute (NHLBI) type C.

Clinical Exclusion Criteria:

  1. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation MI (STEMI)
  2. Subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support, intractable ventricular arrhythmias, or ongoing intractable angina
  3. Subject has received an organ transplant or is on a waiting list for an organ transplant
  4. Subject is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure
  5. Planned PCI (including staged procedures) or CABG after the index procedure
  6. Subject previously treated at any time with intravascular brachytherapy
  7. Subject has a known allergy to contrast (that cannot be adequately premedicated) and/or the trial stent system or protocol-required concomitant medications (e.g., platinum, platinum-chromium alloy, stainless steel, everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors, or aspirin)
  8. Subject has one of the following (as assessed prior to the index procedure):Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 24 months; Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.);Planned procedure that may cause non-compliance with the protocol or confound data interpretation
  9. Subject is receiving chronic (≥72 hours) anticoagulation therapy (i.e., heparin, coumadin) for indications other than acute coronary syndrome
  10. Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3
  11. Subject has a white blood cell (WBC) count < 3,000 cells/mm3
  12. Subject has documented or suspected liver disease, including laboratory evidence of hepatitis
  13. Subject is on dialysis or has baseline serum creatinine level >2.0 mg/dL (177µmol/L)
  14. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
  15. Subject has had a history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months
  16. Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding
  17. Subject has signs or symptoms of active heart failure (i.e., NYHA class IV) at the time of the index procedure
  18. Subject is participating in another investigational drug or device clinical trial that has not reached its primary endpoint
  19. Subject intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure
  20. Subject with known intention to procreate within 12 months after the index procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure)
  21. Subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential)

Angiographic Exclusion Criteria:

  1. Planned treatment of more than 3 lesions.
  2. Planned treatment of lesions in more than 2 major epicardial vessels
  3. Planned treatment of a single lesion with more than 1 stent
  4. Subject has 2 target lesions in the same vessel that are separated by less than 15 mm (by visual estimate)
  5. Target lesion(s) is located in the left main
  6. Target lesion(s) is located within 3 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCx) coronary artery by visual estimate.
  7. Target lesion(s) is located within a saphenous vein graft or an arterial graft
  8. Target lesion(s) will be accessed via a saphenous vein graft or arterial graft
  9. Target lesion(s) with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire crossing
  10. Target lesion(s) treated during the index procedure that involves a complex bifurcation (e.g., bifurcation lesion requiring treatment with more than 1 stent)
  11. Target lesion(s) is restenotic from a previous stent implantation or study stent would overlap with a previous stent
  12. Subject has unprotected left main coronary artery disease (>50% diameter stenosis)
  13. Subject has been treated with any type of PCI (i.e., balloon angioplasty, stent, cutting balloon atherectomy) within 24 hours prior to the index procedure
  14. Thrombus, or possible thrombus, present in the target vessel (by visual estimate)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: NG PROMUS stent
Single-arm treatment group receiving interventional NG PROMUS study stent
Dispositivo: Percutaneous coronary intervention (NG PROMUS)
Interventional coronary artery stenting with NG PROMUS study stent.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Technical Success Rate
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day
Technical success is defined as successful delivery and deployment of the study stent to the target lesion, without balloon rupture or stent embolization, and post-procedure diameter stenosis of <30% assessed in 2 near-orthogonal projections with TIMI 3 flow in the target lesion, as visually assessed by the physician
Participants will be followed for the duration of hospital stay, an expected average of 1 day

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Target Lesion Revascularization (TLR) Rate
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days

Target lesion revascularization is any ischemia-driven repeat percutaneous intervention, to improve blood flow, of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion. A TLR will be considered as ischemia-driven if the target lesion diameter stenosis is >/= 50% by QCA and there is presence of clinical or functional ischemia which cannot be explained by other coronary or graft lesions. Clinical or functional ischemia is any of the following:

  • The subject has a positive functional study corresponding to the area served by the target lesion.
  • The subject has ischemic ECG changes at rest in a distribution consistent with the target vessel.
  • The subject has ischemic symptoms referable to the target lesion. A TLR will be considered as ischemia-driven if the lesion diameter stenosis is >/= 70% by QCA even in the absence of clinical or functional ischemia.
Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
Target Lesion Failure (TLF) Rate
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days

Target lesion failure is any ischemia-driven revascularization of the target lesion, MI (Q-wave and non-Q-wave) related to the target vessel, or (cardiac) death. For the purposes of this protocol, if it cannot be determined with certainty whether the MI was related to the target vessel, it will be considered a TLF.

The MI definition used for Target Lesion Failure was the PLATINUM MI definition.
Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
Target Vessel Revascularization (TVR) Rate
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days

Target vessel revascularization is defined as a TLR or a TVR remote. Target vessel revascularization remote is any ischemia-driven repeat percutaneous intervention, to improve blood flow, or bypass surgery of not previously existing lesions diameter stenosis >/= 50% by QCA in the target vessel, excluding the target lesion. A TVR will be considered ischemia-driven if the target vessel diameter stenosis is >/= 50% by QCA and any of the following are present:

  • The subject has a positive functional study corresponding to the area served by the target vessel.
  • The subject has ischemic ECG changes at rest in a distribution consistent with the target vessel.
  • The subject has ischemic symptoms referable to the target vessel. A TVR will also be considered as ischemia-driven if the lesion diameter stenosis is >/=70% even in the absence of clinical or functional ischemia.
Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
Target Vessel Failure (TVF) Rate
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days

Target vessel failure is any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.

The MI definition used was the PLATINUM MI definition.
Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
Myocardial Infarction (MI, Q-wave and Non-Q-wave) Rate
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
MI will be defined according to the PLATINUM Definition of MI with evidence pre-specified for i) Spontaneous, ii) PCI-related, iii) CABG related, and iv) autopsy evidence criteria.
Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
Cardiac Death Rate
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days

Cardiac death is defined as death due to any of the following.

  • Acute MI
  • Cardiac perforation/pericardial tamponade
  • Arrhythmia or conduction abnormality
  • CVA through hospital discharge or CVA suspected of being related to the procedure
  • Death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery
  • Any death in which a cardiac cause cannot be excluded
Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
Non-cardiac Death Rate
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days

Non-cardiac death is defined as a death not due to any of the following:

  • Acute MI
  • Cardiac perforation/pericardial tamponade
  • Arrhythmia or conduction abnormality
  • CVA through hospital discharge or CVA suspected of being related to the procedure
  • Death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery
  • Any death in which a cardiac cause cannot be excluded
Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
All Death Rate
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
Death is categorized as cardiac or non-cardiac deaths.
Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
Cardiac Death or MI Rate
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days

Any cardiac death or MI event meeting the criteria defined for a cardiac death or MI.

MI definition used was the PLATINUM definition for MI.
Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
All Death or MI Rate
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days

Any all-cause mortality event or MI meeting the criteria defined for any death or MI.

MI definition used was the PLATINUM definition for MI.
Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
All Death/MI/TVR Rate
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days

Any event meeting the pre-specified criteria for any death, MI, or TVR.

MI definition used was the PLATINUM definition for MI.
Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
Stent Thrombosis Rate (by Academic Research Consortium [ARC] Definitions)
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days

Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guide catheter has been removed and the patient left the catheterization lab.

Timing:

  • Acute stent thrombosis*: 0 24 hours after stent implantation
  • Subacute stent thrombosis*: >24 hours to 30 days after stent implantation
  • Late stent thrombosis: >30 days to 1 year after stent implantation
  • Very late stent thrombosis: >1 year after stent implantation * Acute/subacute can also be replaced by early stent thrombosis. Early stent thrombosis is 0 30 days.

Stent thrombosis may be defined as:

  • Confirmed/definite
  • Probable
  • Possible

Confirmed/Definite (is considered either angiographic confirmed or pathologic confirmed)
Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days
Clinical Procedural Success Rate
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day

Clinical procedural success is post-procedure diameter stenosis <30% in 2 near-orthogonal projections with TIMI 3 flow in all target lesions, as visually assessed by the physician, without the occurrence of in-hospital MI, TVR, or cardiac death.

MI definition used was the PLATINUM definition for MI.
Participants will be followed for the duration of hospital stay, an expected average of 1 day
In-stent Percent Diameter Stenosis (%DS)
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day

As measured by an independent angiographic core laboratory using quantitative coronary angiography (QCA), the % diameter stenosis of the in-stent region.

Percent diameter stenosis: Relative changes that occur in the percent diameter stenosis are provided by the following relationship: % diameter stenosis= (1-[Minimum Lumen Diameter/Reference diameter]) x 100.
Participants will be followed for the duration of hospital stay, an expected average of 1 day
In-segment Percent Diameter Stenosis (%DS)
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day

As measured by an independent angiographic core laboratory using quantitative coronary angiography (QCA), the % diameter stenosis of the in-segment region (in-segment includes the stented region and 5 mm edge regions).

Percent diameter stenosis: Relative changes that occur in the percent diameter stenosis are provided by the following relationship: % diameter stenosis= (1-[Minimum Lumen Diameter/Reference diameter]) x 100.
Participants will be followed for the duration of hospital stay, an expected average of 1 day
In-stent Minimum Lumen Diameter (MLD)
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day

As measured by an independent angiographic core laboratory using quantitative coronary angiography (QCA); the minimum lumen diameter (MLD) measured at the in-stent region.

The MLD is the mean minimum lumen diameter (mm) from 2 orthogonal views.
Participants will be followed for the duration of hospital stay, an expected average of 1 day
In-segment Minimum Lumen Diameter (MLD)
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day

As measured by an independent angiographic core laboratory using quantitative coronary angiography (QCA); the minimum lumen diameter (MLD) measured at the in-segment region (in-segment includes the stented region and 5 mm edge regions).

The MLD is the mean minimum lumen diameter (mm) from 2 orthogonal views.
Participants will be followed for the duration of hospital stay, an expected average of 1 day
Acute Gain
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day
Acute gain, as measured by angiographic core lab
Participants will be followed for the duration of hospital stay, an expected average of 1 day
Vessel Area
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day
As measured by IVUS, the mean vessel area (mm2).
Participants will be followed for the duration of hospital stay, an expected average of 1 day
Stent Area
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day
As measured by IVUS, the area of the stent.
Participants will be followed for the duration of hospital stay, an expected average of 1 day
Lumen Area
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day
As measured by IVUS, the area of the lumen.
Participants will be followed for the duration of hospital stay, an expected average of 1 day
Vessel Volume
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day
As measured by IVUS, the volume of the vessel.
Participants will be followed for the duration of hospital stay, an expected average of 1 day
Stent Volume
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day
As measured by IVUS, the volume of the stent.
Participants will be followed for the duration of hospital stay, an expected average of 1 day
Lumen Volume
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day
As measured by IVUS, the volume of the lumen.
Participants will be followed for the duration of hospital stay, an expected average of 1 day
Incomplete Apposition
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day

Incomplete apposition rate, as measured by the IVUS core lab.

Binary assessment of presence of one or more stent struts separated from the vessel wall as detected through intravascular ultrasound (IVUS).
Participants will be followed for the duration of hospital stay, an expected average of 1 day
Percent Net Volume Obstruction
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day
The percentage of volume obstruction, as measured by the IVUS core lab.
Participants will be followed for the duration of hospital stay, an expected average of 1 day
Longitudinal Stent Deformation
Lasso di tempo: Participants will be followed for the duration of hospital stay, an expected average of 1 day
Longitudinal stent deformation, evidenced by longitudinal compression or elongation, as the result of crossing a newly deployed stent with a second device, (such as a balloon catheter, stent system or IVUS catheter), causing the second device to become caught on the stent when the second device is advanced or retracted.
Participants will be followed for the duration of hospital stay, an expected average of 1 day

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Boston Scientific Corporation

Investigatori

  • Investigatore principale: John A Ormiston, MBChB, FRACP, FRACR, Mercy Angiography Unit, Ltd. Mercy Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 novembre 2012

Completamento primario (Effettivo)

1 marzo 2013

Completamento dello studio (Effettivo)

1 marzo 2013

Date di iscrizione allo studio

Primo inviato

5 ottobre 2012

Primo inviato che soddisfa i criteri di controllo qualità

9 ottobre 2012

Primo Inserito (Stima)

10 ottobre 2012

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

15 aprile 2014

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 marzo 2014

Ultimo verificato

1 marzo 2014

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • NG PROMUS Clinical Trial S2294

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Disfunsione dell'arteria coronaria

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Nigeria

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi